62 research outputs found
Pharmacological treatment of mixed states
Get PDFMixed states in bipolar disorder have been neglected, and the data concerning treatment of these conditions have been relatively obscure. To address this, we systematically reviewed published pharmacological treatment data for "mixed states/episodes" in mood disorders, including "with mixed features" in DSM-5. We searched PubMed, MEDLINE, The Cochrane Library, clinicaltrials.gov, and controlled-trials.com (with different combinations of the following keywords: "mixed states/features," "bipolar," "depressive symptoms/bipolar depression," "manic symptoms," "treatment," "DSM-5") through to October 2016. We applied a quality-of-evidence approach: first-degree evidence=randomized placebo-controlled studies of pharmacological interventions used as monotherapy; second-degree evidence=a similar design in the absence of a placebo or of a combination therapy as a comparative group; third-degree evidence=case reports, case series, and reviews of published studies. We found very few primary double-blind, placebo-controlled studies on the treatment of mixed states: the preponderance of available data derives from subgroup analysis performed on studies that originally involved manic patients. Future research should study the effects of treatments in mixed states defined using current criteria
İki uçlu bozukluk tip ı tanılı hastalarda metabolik sendrom görülme sıklığı ve sağaltımında kullanılan ilaçlarla arasındaki ilişki
No full textBipolar bozukluk tip ı tanılı hastalar ve birinci derece akrabalarında yapısal beyin görüntüleme ve nörobilişsel işlevler
No full text
Bidirectional relationships between general medical conditions and bipolar disorder: treatment considerations
No full textIncreased medical co-morbidity is one of the underlying causes of excess and premature mortality in bipolar disorder. This increased prevalence of medical conditions is likely to result from a range of different factors. Some attention in recent years has been devoted to intrinsic illness factors resulting in excessive allostatic load and oxidative stress potentially predisposing to physical morbidity. Some other contributors have also been identified as unhealthy lifestyle habits and unwanted effects of pharmacological treatment. Irrespective of causality, risk minimization can be obtained by systematically addressing physical needs into the management of bipolar disorder. This can be achieved with a range of interventions including regular monitoring of physical health, tailored management of unhealthy lifestyle choices, and pharmacological optimization.</p
Acetazolamide for Bipolar Disorders: A Scoping Review
No full textAcetazolamide, a carbonic anhydrase inhibitor, is used to treat a variety of ailments. It has been highlighted for its potential to benefit people with bipolar disorders, for whom there are clear current unmet treatment needs. This scoping review sought to synthesise all available evidence related to the potential effects of acetazolamide on symptoms related to bipolar disorder, acceptability and tolerability, and intervention characteristics (e.g., dose and duration). Following publication of the review protocol, the Pubmed, Embase, and PsycInfo databases were searched (all dated to 31 August 2022). A systematic approach was undertaken to identify eligible articles and extract relevant data from these. Five studies were included, assessing a total of 50 patients treated with acetazolamide. Most patients were from two open-label trials, while the others were case reports. Approximately one third of patients were experiencing psychosis or mania before treatment initiation, and one third had refractory depression. Forty-four percent of patients were estimated to achieve a response (not seemingly affected by the baseline episode type, acetazolamide dose, or duration), while a further 22% appeared to experience minimal benefits from the intervention. Acetazolamide was generally reported to be tolerated well and acceptable for up to 2 years, although reporting for acceptability and tolerability was suboptimal. The reviewed evidence is extremely limited in size and methodology (e.g., no randomised studies, blinding, or standardised outcome assessment). We posit that the current findings are sufficiently encouraging to recommend substantive clinical trials, but we emphasise that at present, the evidence is exceedingly preliminary, and there remains evident uncertainty as to whether acetazolamide could be a viable treatment for bipolar disorders
Reliability and Validity Of The DSM-5 Level 2 Depression Scale- Turkish Version (Child Form for 11-17 years and Parent Form for 6-17 Years)
No full textIntroduction: This study aimed to assess the reliability and validity of the Turkish version of The DSM-5 Level 2 Depression Scale.
Method: The study group included a case group that consisted of a clinical sample diagnosed with depressive disorder that continued treatment in a child and adolescent psychiatry unit and a community sample. The study was carried out with 218 children and 160 parents. The Child Depression Inventory and Strengths and Difficulties Questionnaire- Parent Form were used along with the DSM-5 Level 2 Depression Scale for assessment.
Results: In reliability analyses, Cronbach alpha internal consistency coefficient was found to be very high for child and parent forms (0.965/0.952). Item- total score correlation coefficients are high and very high, respectively and were found to be consistent with the original structure of the scale (0.725 and 0.864 for child form- 0.644 and 0.839 for parent form) As for concurrent validity, child form had a high correlation with the Childrens Depression Inventory while parent form had a significant correlation with Strengths and Difficulties Questionnaire- Parent Form (r=0.853 p [JCBPR 2017; 6(1.000): 15-21
Validity and Reliability of the Turkish Version for DSM-5 Level 2 Anger Scale (Child Form for Children Aged 11-17 Years and Parent Form for Children Aged 6-17 Years)
Full text linkIntroduction: This study aimed to assess the validity and reliability of the Turkish version of Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Level 2 Anger Scale
Country-level gender inequality is associated with structural differences in the brains of women and men
Full text linkAgustín Ibañez, Daniza Ivanovic, Andrea Jackowski, Pablo Leon-Ortiz, Christine Lochner, Carlos López-Jaramillo, Hilmar Luckhoff, Raffael Massuda, Philip McGuire, Jun Miyata Romina Mizrahi, Robin Murray, Aysegul Ozerdem, Pedro M Pan, Mara Parellada, Lebogan Phahladira, Juan P Ramirez-Mahaluf, Ramiro Reckziegel, Tiago Reis Marques, Francisco Reyes-Madrigal, Annerine Roos, Pedro Rosa, Giovanni Salum, Freda Scheffler, Gunter Schumann, Mauricio Serpa, Dan J Stein, Angeles Tepper, Jeggan Tiego, Tsukasa Ueno, Eduardo A Undurraga, Pedro Valdes-Sosa, Isabel Valli, Mirta Villarreal, Toby T Winton-Brown, Nefize Yalin, Francisco Zamorano, Marcus V Zanetti; cVEDA; Anderson M Winkler, Daniel S Pine, Sara Evans-Lacko, Nicolas A CrossleyGender inequality across the world has been associated with a higher risk to mental health problems and lower academic achievement in women compared to men. We also know that the brain is shaped by nurturing and adverse socio-environmental experiences. Therefore, unequal exposure to harsher conditions for women compared to men in gender-unequal countries might be reflected in differences in their brain structure, and this could be the neural mechanism partly explaining women's worse outcomes in gender-unequal countries. We examined this through a random-effects meta-analysis on cortical thickness and surface area differences between adult healthy men and women, including a meta-regression in which country-level gender inequality acted as an explanatory variable for the observed differences. A total of 139 samples from 29 different countries, totaling 7,876 MRI scans, were included. Thickness of the right hemisphere, and particularly the right caudal anterior cingulate, right medial orbitofrontal, and left lateral occipital cortex, presented no differences or even thicker regional cortices in women compared to men in gender-equal countries, reversing to thinner cortices in countries with greater gender inequality. These results point to the potentially hazardous effect of gender inequality on women's brains and provide initial evidence for neuroscience-informed policies for gender equality.Versión publicad
The Reliability and Validity of the Turkish version of the DSM-5 Level 2 Irritability Scale
No full text- …
